During the biotech industry's extended market bull run there has been a notable resurgence of interest in advanced gene and cell therapies. In fact, the Washington-based Alliance for Regenerative Medicine (ARM), an international advocacy organization representing the regenerative medicine and advanced therapies community, hailed 2014 as a breakout year for the sector during its annual state-of-the-industry briefing presented at the Biotech Showcase meeting in January.